Pubblicazioni

Autori:

Favaloro, Emmanuel J; Pasalic, Leonardo; Lippi, Giuseppe

Titolo:

Oral Anticoagulation Therapy: An Update on Usage and Costs in the Endemic COVID-19 Era

Anno:

2025

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

Sì

Nome rivista:

JOURNAL OF CLINICAL MEDICINE

ISSN Rivista:

2077-0383

N° Volume:

14

Numero o Fascicolo:

8

Intervallo pagine:

2591-2591

Parole chiave:

Oral Anticoagulation Therapy; COVID-19; Direct Oral Anticoagulants; Apixaban; Warfarin

Breve descrizione dei contenuti:

Background/Objectives: Oral anticoagulant (OA) therapy (OAT) may be prescribed to patients for a variety of reasons, with several agent classes currently available as well as emerging. The classical oral anticoagulants are represented by vitamin K antagonists (VKAs), including warfarin, and the more modern alternatives comprise the direct oral anticoagulants (DOACs). We aimed to assess usage of OAs over time in Australia, especially focusing on the period of the coronavirus disease 2019 (COVID-19) pandemic and its transition to an endemic phase, to assess for any trends. Methods: Using data from the pharmaceutical benefits scheme (PBS), Medicare and other online sites, we specifically assessed for changes in OA prescription and cost patterns over the period 1992–2024, but focusing especially on the period 2020–2024 inclusive. Results: Apixaban is now the most prescribed OA in Australia. Costs of OAT prescriptions have steadily increased over the data capture period, reaching half a billion dollars in 2023. Interestingly, costs have started to fall, seemingly driven by the release of DOAC generics and PBS pricing adjustments. We could identify no clear signals related to COVID-19-related changes in prescription trends, contrary to previous reports in other locations. Conclusions: We provide Australian data on both OA usage as well as costs. Despite an ongoing trend to increasing use of DOACs over VKAs, we could not identify any specific COVID-19-related changes.

Pagina Web:

https://www.mdpi.com/2077-0383/14/8/2591

Id prodotto:

145019

Handle IRIS:

11562/1159367

ultima modifica:

29 aprile 2025

Citazione bibliografica:

Favaloro, Emmanuel J; Pasalic, Leonardo; Lippi, Giuseppe, Oral Anticoagulation Therapy: An Update on Usage and Costs in the Endemic COVID-19 Era «JOURNAL OF CLINICAL MEDICINE» , vol. 14 , n. 8 , 2025 , pp. 2591-2591

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo